Faex Health Announces Investigational AI Screening Capabilities for Ebola and H. pylori, Expanding Gut Health Platform to 18 Conditions
PR Newswire
NEW YORK, Nov. 20, 2026
Unveiled during HITLAB's Center for AI Testing and Evidence program, the new capabilities aim to identify potential health warning signs through smartphone images of stool, without laboratory testing for the initial assessment
NEW YORK, Nov. 20, 2026 /PRNewswire/ -- Faex Health, a digital health company that has developed AI-powered tools to help people better understand and track digestive wellness, announced the addition of Ebola virus disease and Helicobacter pylori (H. pylori) to its investigational pre-screening platform, expanding its internally validated panel to 18 gastrointestinal and related health conditions. The announcement was made by Faex Health Co-Founder and CEO Landon Nattrass during a virtual presentation hosted by HITLAB's Center for AI Testing and Evidence (CAITE).
The two new indications represent a significant expansion of Faex Health's research into how artificial intelligence and computer vision can identify potential health warning signs through photographs of human stool. Using a standard smartphone camera, the platform analyzes visual characteristics, including color, consistency, texture, blood, mucus, and other anomalies, to generate preliminary health indicators that may warrant further medical evaluation.
While H. pylori and Ebola present dramatically different public health challenges, both underscore the potential value of accessible, noninvasive health monitoring, particularly in communities where traditional diagnostic infrastructure may be limited or difficult to access.
"From one of the world's most widespread bacterial infections to one of its most dangerous viral diseases, H. pylori and Ebola illustrate the extraordinary range of public health challenges Faex Health is working to address," Nattrass said. "By expanding our investigational platform to include both conditions, we are exploring how technology people already carry in their pockets could help bridge gaps in health monitoring, particularly where access to traditional testing is limited."
Addressing Two Distinct Global Health Challenges
H. pylori, a bacterial infection affecting approximately half of the world's population, is a major cause of peptic ulcer disease and an established risk factor for gastric cancer. Many infected individuals experience no symptoms, making identification and treatment particularly challenging. Conventional testing typically requires a urea breath test, stool antigen test, or endoscopic biopsy.
Faex Health's newly announced H. pylori indication is designed to explore whether AI analysis of stool images can provide an accessible preliminary signal that encourages appropriate follow-up testing and medical evaluation. Ebola virus disease, by contrast, is a rare but potentially fatal infectious disease that can cause severe gastrointestinal symptoms, including diarrhea and significant fluid loss. Confirmatory diagnosis requires specialized laboratory testing, typically using reverse transcription polymerase chain reaction (RT-PCR).
Faex Health is investigating whether visual patterns in stool could contribute to preliminary triage assessments in outbreak environments, particularly where laboratory resources are limited or delays in testing may complicate public health response. The technology is not intended to diagnose Ebola or replace established laboratory testing, infection-control procedures or clinical assessment. Both new indications have undergone internal validation using Faex Health's proprietary datasets. Neither has entered clinical trials, and neither has received U.S. Food and Drug Administration (FDA) clearance or approval.
Expanding AI-Powered Monitoring Across 18 Health Conditions
With the addition of Ebola and H. pylori, Faex Health's investigational platform now encompasses 18 conditions across five clinical categories, including infectious diseases; colorectal and gastrointestinal bleeding conditions; chronic and inflammatory disorders; functional and anorectal conditions; and hepatic, pancreatic and microbiome-related conditions.
The panel includes investigational indicators associated with colorectal cancer risk, precancerous polyps, Crohn's disease, ulcerative colitis, irritable bowel syndrome, celiac disease, gastrointestinal bleeding, and other digestive health concerns.
Unlike traditional stool testing methods that capture information at a single point in time, Faex Health is designed to support ongoing monitoring through repeated smartphone images. Its computer vision technology evaluates stool characteristics consistently over time, creating the potential to identify changes and patterns that may otherwise go unrecorded. The platform also provides Bristol Stool Form Scale classifications and evaluates seven categories of visual anomalies.
"Your gut produces information about your health every day, yet most of that information is never captured or evaluated," Nattrass added. "Our vision is to make monitoring those changes as routine as checking your heart rate or tracking your sleep. Rather than relying exclusively on isolated tests, we believe longitudinal data could eventually provide healthcare professionals and individuals with a more complete picture of digestive health."
Advancing Clinical Research and Commercial Deployment
Faex Health's broader research program includes the ongoing FECAL-AI clinical trial at Hospital Dr. Sótero del Río in Chile, where investigators are evaluating the platform's image-derived signals in colorectal cancer screening against conventional fecal immunochemical testing (FIT).
The company is also exploring the design of a larger-scale colorectal cancer screening study in the United Kingdom involving the National Health Service (NHS) and National Institute for Health and Care Research (NIHR). That proposed program remains in the planning stage and has not received protocol approval.
Commercially, Faex Health reports four signed agreements representing approximately 150,000 covered lives, with its first 50,000 covered lives active as of November 2026. Beyond its current 18-condition investigational panel, Faex Health is conducting exploratory research into stool-visible indicators associated with more than 100 additional health conditions. Nattrass will further discuss the company's research, clinical development and vision for AI-powered health monitoring at the HITLAB Innovators Summit on Dec. 3 at the Microsoft Technology Center in Times Square, New York City.
For more information or to schedule an interview, contact Shawna Seldon at shawna@themaverickpr.com or +1 917-971-7852.
About Faex Health
Faex Health is a health technology company that has developed AI-powered solutions for preventive gastrointestinal health monitoring. Using computer vision, machine learning, and smartphone-based image analysis, the Faex platform helps users capture digestive health information, monitor patterns over time, and access personalized educational wellness insights. The company has developed solutions designed to support individuals, healthcare providers, health plans, employers, and population health organizations. Faex Health's investigational clinical applications are intended to complement established medical screening and diagnostic pathways, not replace them. For more information, visit FaexHealth.com. Download the Faex Health app on Apple Store for iOS and Google Play for Android. Continue the conversation on LinkedIn, Facebook, TikTok, X, Reddit, and Instagram.
Regulatory and Clinical Research Disclosure: Faex Health is investigational and has not received FDA clearance or approval. Its outputs are preliminary pre-screening indicators intended for health awareness and professional review, not medical diagnoses. All 18 indications have undergone internal validation, but these findings have not been independently replicated or peer reviewed as a complete panel. Clinical trials have not begun for the Ebola or H. pylori indications. The platform is not a substitute for laboratory testing, established screening protocols or professional medical evaluation.
View original content to download multimedia:https://www.prnewswire.com/news-releases/faex-health-announces-investigational-ai-screening-capabilities-for-ebola-and-h-pylori-expanding-gut-health-platform-to-18-conditions-302947230.html
SOURCE Faex Health

